+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
ID07570823

Phase 3 Study Comparing SCTB35 Plus Gemcitabine and Oxaliplatin to Rituximab Plus Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Led by Sinocelltech Ltd. · Updated on 2026-08-13

101

Participants Needed

1

Research Sites

73 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of SCTB35 combined with Gemcitabine and Oxaliplatin compared to Rituximab combined with Gemcitabine and Oxaliplatin in patients with relapsed or refractory diffuse large B-cell lymphoma. The study is a Phase 3 randomized trial designed to assess these treatments in adults aged 18 to 80 who have previously undergone therapy including an anti-CD20 monoclonal antibody and chemotherapy. Participants receive either SCTB35 by subcutaneous injection plus intravenous Gemcitabine and Oxaliplatin, or intravenous Rituximab with Gemcitabine and Oxaliplatin. These treatments are given for up to eight cycles. The study compares the two treatment combinations to evaluate their effects and safety. During the study, participants will be monitored for adverse events and progression-free survival for up to approximately three years. Other assessments include overall survival, response rates, duration of response, and blood levels of SCTB35. Safety and immune response markers will be tracked, with follow-up visits scheduled throughout the study duration to thoroughly evaluate treatment outcomes and participant health.

CONDITIONS

Brief Title

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here